Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant pr…
| Periodo | 2027-03 | 2016-02 | 2015-10 | 2015-07 |
|---|---|---|---|---|
| Real | — | $0.51 | $0.95 | $0.43 |
| Estimado | — | $0.53 | $0.44 | $0.41 |
| Sorpresa | — | -3.8% | +115.9% | +4.9% |
| Métrica | SNN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 68.0% | 57.4% | +10.6% |
| Operating Margin | 12.9% | -34.4% | +47.3% |
| Net Margin | 10.1% | -32.5% | +42.6% |
| FCF Margin | 13.8% | -12.6% | +26.4% |
| ROE | 11.8% | -39.2% | +51.0% |
| ROA | 6.0% | -30.9% | +36.9% |
| Current Ratio | 2.57 | 2.73 | -0.16 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 6.0% | — |
| ✓Flujo de caja operativo positivo | $1.3B | $987M |
| ✓Rentabilidad sobre activos al alza | 6.0% | 4.0% |
| ✓Caja operativa/activos supera al ROA | 12.3% | ROA 6.0% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 2.57 | 2.89 |
| ✓Sin aumentar el nº de acciones | 873M | 876M |
| ✗Margen bruto al alza | 68.0% | 69.6% |
| ✓Rotación de activos al alza | 0.59 | 0.56 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 13.8% |
| ✗ROCE > 10 % | 9.0% |
| ✓Ventas > 5 %/año (3 años) | 5.7% |
| ✓Deuda neta/EBITDA < 3x | 1.9x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 11.8% |
Riesgo de quiebra (Altman Z 3.3): zona segura
SMITH & NEPHEW PLC cotiza a 29.06 USD y tiene una capitalización bursátil de $12.2B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud